Atopic Dermatitis Management

Core Treatment Algorithm

The American Academy of Dermatology recommends applying emollients liberally and frequently throughout the day to maintain skin hydration and improve barrier function, as the foundation of all atopic dermatitis management 1, 2
Apply emollients immediately after bathing when skin is still slightly damp to maximize moisture retention and therapeutic benefit, as suggested by the American Academy of Dermatology 2, 3
Replace regular soaps with soap-free cleansers or dispersable cream substitutes to prevent removal of natural skin lipids that worsen the condition, in line with guidelines from the American Academy of Dermatology 2, 3
Start with topical corticosteroids as first-line anti-inflammatory therapy for active disease, with potency based on anatomic location, as recommended by the American Academy of Dermatology 1
Select corticosteroid potency based on anatomic location: face and intertriginous areas should use only mild-potency preparations, while body and extremities can use mild-to-moderate potency preparations, according to the American Academy of Dermatology 2, 3, 4
Apply topical corticosteroids once daily to affected areas until the flare resolves, typically for short periods, as suggested by the American Academy of Dermatology 2, 4
Use the least potent preparation required to control the eczema to avoid unnecessarily potent steroids that increase side effect risk, in line with guidelines from the American Academy of Dermatology 2, 3

After achieving disease control, continue applying topical corticosteroids 1-2 times weekly or topical calcineurin inhibitors 2-3 times weekly to previously affected areas to reduce subsequent flares and lengthen time to relapse, as recommended by the American Academy of Dermatology 5, 6, 2
The American Academy of Dermatology strongly recommends this proactive approach, which represents a shift from purely reactive treatment 5, 6

Topical calcineurin inhibitors can be used in conjunction with topical corticosteroids as first-line treatment, particularly for sensitive areas where steroid side effects are concerning, as suggested by the American Academy of Dermatology 1

Sedating antihistamines may provide short-term benefit during severe flares primarily through their sedative properties to improve sleep, not through direct antipruritic effects, according to the American Academy of Dermatology 2, 3, 4
Non-sedating antihistamines have little to no value in atopic dermatitis management, as stated by the American Academy of Dermatology 2, 3
Monitor for secondary bacterial infection which requires appropriate antibiotic treatment, as recommended by the American Academy of Dermatology 2, 3
Watch for viral infections, particularly eczema herpeticum, which requires prompt antiviral therapy, according to the American Academy of Dermatology 3

Do not perform routine allergy testing without clinical history suggesting specific allergies, as recommended by the American Academy of Dermatology 5, 6
Do not implement food elimination diets based solely on allergy test results without documented clinical reactions, according to the American Academy of Dermatology 5, 6
Do not continue ineffective first-line treatment indefinitely—if no improvement occurs after appropriate trial, escalate therapy or refer to dermatology, as suggested by the American Academy of Dermatology 2, 3, 4
Avoid using potent topical corticosteroids on the face, as this is a critical error that leads to skin atrophy and other complications, according to the American Academy of Dermatology 2, 3

Phototherapy is the next step for patients who fail optimized topical regimens with emollients and topical anti-inflammatory therapies, as recommended by the American Academy of Dermatology 1
Refer to dermatology when failure to respond to first-line treatment occurs, diagnostic uncertainty exists, second-line treatments are being considered, or disease significantly impacts quality of life, as suggested by the American Academy of Dermatology 1, 2, 3, 4

Infants are particularly susceptible to topical corticosteroid side effects due to high body surface area-to-volume ratio—use only mild-potency preparations, according to the American Academy of Dermatology 3
Adolescents have lower systemic absorption risk and can tolerate moderate-potency preparations on the body more safely than younger children, as stated by the American Academy of Dermatology 4

The American Academy of Dermatology recommends a stepwise treatment algorithm for atopic dermatitis, starting with liberal emollient application and soap-free cleansers, progressing to topical corticosteroids, then phototherapy, and finally systemic biologics or JAK inhibitors for moderate-to-severe refractory disease 7

The American Academy of Dermatology makes strong recommendations for dupilumab, tralokinumab, abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis failing phototherapy or when phototherapy is not viable 7
Tacrolimus and pimecrolimus are effective steroid-sparing agents for both acute and maintenance therapy, particularly useful for sensitive areas where corticosteroid side effects are concerning, with no signal for cancer risk emerging in clinical use 8

The American Academy of Dermatology recommends continuing topical corticosteroids 1-2 times weekly or topical calcineurin inhibitors 2-3 times weekly to previously affected skin to reduce subsequent flares, representing a paradigm shift from purely reactive treatment 9

Structured educational programs are strongly recommended as adjuncts to conventional therapy, improving outcomes by teaching disease recognition, trigger avoidance, proper medication application, and moisturization techniques, and addressing topical steroid phobia through education 8, 9

The International Eczema Council recommends a systematic approach before systemic therapy, considering alternate or concomitant diagnoses, optimizing topical therapy, treating coexistent infection, assessing impact on quality of life, and considering phototherapy before systemic agents 8, 10